Related Experiment Video

Updated: Mar 13, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

6.3K

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents

Héloïse M Delagrèverie1, Constance Delaugerre1, Sharon R Lewin2

  • 1INSERM U941, Université Paris Diderot, Laboratoire de Virologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris , France.

Open Forum Infectious Diseases
|October 21, 2016
PubMed

Insights

Strategies targeting the latent HIV-1 reservoir, including latency reversal agents (LRAs) and immunomodulatory drugs, are being tested in clinical trials to achieve a functional cure for HIV.

Area of Science:

  • Virology
  • Immunology
  • Clinical Medicine

Background:

  • Latently infected cells represent a significant barrier to eradicating human immunodeficiency virus (HIV)-1.
  • Current therapeutic strategies aim to disrupt, eliminate, or control this viral reservoir.

Approach:

  • This review summarizes ongoing clinical trials investigating HIV latency reversal agents (LRAs) and immunomodulatory molecules.
  • It examines strategies designed to reactivate HIV transcription, eliminate infected cells, and control viral replication.

Key Points:

  • LRAs aim to reactivate HIV-1 transcription and virus production from latent reservoirs.
  • Immunomodulatory drugs are explored for reversing latency, blocking proliferation, and enhancing immune control.
  • Clinical trials are evaluating the efficacy and safety of these novel therapeutic approaches.

Conclusions:

  • The development of effective strategies against the latent HIV-1 reservoir is crucial for achieving a functional cure.
  • Challenges remain in comparing and interpreting results from diverse clinical trials.
  • Further research is needed to optimize therapeutic interventions for HIV eradication.
Keywords:
HIV-1anti-HIV agentsclinical triallatency-reversing agentsviral reservoir

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.4K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.0K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.2K
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
987